{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC

Description

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Purpose of Activity

To provide information on the use of lenvatinib as first-line treatment and other, second-line treatments, for unresectable hepatocellular carcinoma (HCC).

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Propose encouraging second-line treatments for HCC patients having prior sorafenib therapy.
  2. Appraise the results of the phase 3 evaluation of lenvatinib vs. sorafenib as first-line treatment for unresectable HCC.
Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: OT1218
Published: Dec 2018
Expires: 12/31/2020
Sources: Oncology Times
Passing Score: 7/10 (70%)
Authors: Richard Simoneaux
Categories: Oncology
Specialties: Oncology